Ayala Pharmaceuticals Overview
- Founded
- 2017
- Status
- Public
- Employees
- 31
- Stock Symbol
- AYLA
- Share Price
- $3.65
- (As of Monday Closing)
Ayala Pharmaceuticals General Information
Description
Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company's current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma-secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma-secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell-specific leukemia.
Contact Information
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
NAS
Primary Office
- 1007 North Orange Street
- 4th Floor
- Wilmington, DE 19802
- United States
+1 (857) 000-0000
Ayala Pharmaceuticals Timeline
Ayala Pharmaceuticals Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.65 | $3.66 | $3.50 - $14.95 | $51M | 13.9M | 31K | -$2.87 |
Ayala Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 |
|---|---|---|---|---|
| EV | 106,264 | 92,272 | ||
| Revenue | 3,364 | 3,708 | 2,334 | 0 |
| EBITDA | (38,709) | (29,595) | (17,561) | (8,986) |
| Net Income | (39,603) | (30,146) | (17,792) | (8,873) |
| Total Assets | 45,744 | 45,828 | 20,054 | 27,125 |
| Total Debt | 493 | 553 | 299 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Ayala Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Ayala Pharmaceuticals‘s full profile, request access.
Request a free trialAyala Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is available in the PitchBook Platform. To explore Ayala Pharmaceuticals‘s full profile, request access.
Request a free trialAyala Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule thera
Biotechnology
Wilmington, DE
31
As of 2021
00000
000000000
00000
00000000
exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in repre
0000000000000
Newtown, PA
00
As of 0000
00000
00000000
00000
00000000
ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolor
0000000000000
Tübingen, Germany
000
As of 0000
00000
000000000
00000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialAyala Pharmaceuticals Competitors (53)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Onconova Therapeutics | Formerly VC-backed | Newtown, PA | 00 | 00000 | 00000000 | 00000 |
| 00000000 | Formerly VC-backed | Tübingen, Germany | 000 | 00000 | 000000000 | 00000 |
| 00000000 000000000 | Formerly VC-backed | London, United Kingdom | 000 | 00000 | 00000000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | Burlingame, CA | 00 | 00000 | 000000 - 000 | 00000 |
| 0000000 000 | Corporation | New York, NY | 00 | 00000 | 00000000 | 00000 |
Ayala Pharmaceuticals Patents
Ayala Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20200085839-A1 | Combination of immunotherapeutics and bisfluoroalkyl-1,4-benzodiazepinone compounds for treating lymphomas | Pending | 24-May-2018 | 00000000000 | |
| US-20200022990-A1 | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating adenoid cystic carcinoma | Pending | 15-May-2018 | 00000000000 | |
| CA-3100202-A1 | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | Pending | 15-May-2018 | 00000000000 | |
| AU-2019271151-A2 | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | Pending | 15-May-2018 | 00000000000 | |
| AU-2019271151-A1 | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | Pending | 15-May-2018 | A61K31/5513 |
Ayala Pharmaceuticals Executive Team (7)
Ayala Pharmaceuticals Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| David Sidransky Ph.D | Self | Chairman & Board Member | 000 0000 |
| Murray Goldberg | Ayala Pharmaceuticals | Board Member | 000 0000 |
| Robert Spiegel MD | Self | Board Member | 000 0000 |
| Roni Mamluk Ph.D | Ayala Pharmaceuticals | Chief Executive Officer & Board Member | 000 0000 |
| Vered Bisker-Leib Ph.D | Self | Board Member | 000 0000 |
Ayala Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAyala Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore Ayala Pharmaceuticals‘s full profile, request access.
Request a free trial